CN106822170A - Application of the NADH in prevention or treatment renal ischemic injury medicine is prepared - Google Patents
Application of the NADH in prevention or treatment renal ischemic injury medicine is prepared Download PDFInfo
- Publication number
- CN106822170A CN106822170A CN201710064412.5A CN201710064412A CN106822170A CN 106822170 A CN106822170 A CN 106822170A CN 201710064412 A CN201710064412 A CN 201710064412A CN 106822170 A CN106822170 A CN 106822170A
- Authority
- CN
- China
- Prior art keywords
- nadh
- ischemic injury
- medicine
- renal ischemic
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of the NADH in prevention or treatment renal ischemic injury medicine is prepared, initiative is found that preventive and therapeutic effect of the NADH for renal ischemic injury, NADH is also disclosed in the application prepared in preventing or treating renal ischemic injury medicine and the formulation that can specifically apply, the exploitation for preventing and treating renal ischemic injury medicine provides truly feasible medicine embodiment.
Description
Technical field
The present invention relates to one kind prevention or treatment renal ischemic injury medicine, more particularly to two nucleoside of nicotinamide adenine
Application of the acid in prevention or treatment renal ischemic injury medicine is prepared.
Background technology
NADH is (referred to as：Cozymase, NAD+), as the required coenzyme in oxidation-reduction process and
(predominantly ADP ribosyltransferase or poly- ADP ribosyls are polymerized NAD+ dependences adenosine diphosphate (ADP) (ADP) ribosyltransferase
Enzyme (PARP), ring ADP ribose polymerases (cADP synthase), III type histon deacetylase (HDAC) (Sirtuins)) can uniquely utilize
Material, participate in cellular material metabolism, energy synthesis, cell DNA repair etc. various physiological activities.
The preparation method of NADH is mainly with yeast as raw material, and yeast is through extracting in boiling water, acetic acid
Lead acid precipitation obtains crude product, is processed through formic acid type cation exchange resin column, refines and obtains.
The first to file (Application No. 201510665849) of applicant discloses NADH and is preparing
Application in preventing and treating heart ischemia damage medicine, it was recently reported that NADH is damaged for heart ischemia
Effect, but influence and effect of the NADH for renal ischemic injury are had no in the prior art.
The content of the invention
The present invention is in a creative way it has further been discovered that NADH is anti-for renal ischemic injury
Control effect.
The present invention provide technical scheme be：
Application of the NADH in prevention or treatment renal ischemic injury medicine is prepared.
Further, the renal ischemic injury is serum urea nitrogen and creatinine rising, renal damage.
Further, the pharmaceutical dosage form is tablet, capsule, granule, pill, supensoid agent, syrup, enteric system
Agent or injection.
On the other hand, the present invention also provides a kind of medicine for preventing or treating renal ischemic injury, and the medicine includes
NADH；Preferably, NADH is the sole active agent of medicine.
The present invention uses above-mentioned technical proposal, compared with prior art, have the following technical effect that：
Of the invention initiative is found that preventive and therapeutic effect of the NADH for renal ischemic injury,
Also disclose NADH prepare prevention or treatment renal ischemic injury medicine in application and
The formulation that can specifically apply, the exploitation for preventing and treating renal ischemic injury medicine provides truly feasible medicine embodiment party
Case.
Brief description of the drawings
Fig. 1 is serum urea nitrogen (BUN) and creatinine (Scr) horizontal testing result in embodiment；
Fig. 2 is the horizontal testing result of sNGAL, uKIM-1 in serum, urine in embodiment；
Fig. 3 is the testing result of PAS staining reaction renal damages in embodiment.
Specific embodiment
Of the invention initiative is found that preventive and therapeutic effect of the NADH for renal ischemic injury,
Also disclose NADH prepare prevention or treatment renal ischemic injury medicine in application and
The formulation that can specifically apply.
The experiment content of application of the present invention to NADH in preventing and treating kidney injury medicine is prepared
Mainly include the following aspects：
1.NAD+ has protective effect to the kidney injury that renal ischemic causes, and can reduce serum urea nitrogen, creatinine water
It is flat.
2.NAD+ has protective effect to the renal damage that renal ischemic causes.
The present invention is described in more detail below by specific embodiment, for a better understanding of the present invention,
But following embodiments are not intended to limit the scope of the invention.
Embodiment one
The present embodiment illustrates that NAD+ has obvious therapeutic action in preventing and treating renal ischemic is damaged by pharmacodynamic experiment.
First, experimental technique
1st, animal operation
Research uses rat, and experimental animal feeding carries out zoopery in MED-X research institutes of Shanghai Communications University.It is all of
Operating process meets Shanghai Communications University's laboratory animal protection and uses rules.Anesthetic selects 7% chloraldurate, anesthesia
Mode is intraperitoneal injection, dosage 1mL/100g.Tail vein injection administration is carried out to rat after anesthesia.Control group injects physiology salt
Water, experimental group injection 5mg/kg NAD+, renal ischemic operation is carried out after administration 30min.After the completion of renal ischemic operation, rat
Raised in Animal House, condition is 22-24 DEG C, the light/dark circulation of 12 hours, and can ad lib water intaking.It is sacrificial after 24h
Domestic animal rat, takes blood, takes urine, takes renal tissue.
2nd, the storage of renal tissue
Kidney take out after, using liquid nitrogen frozen, -80 DEG C of refrigerators are transferred to afterwards and are preserved for a long time, for frozen section and after
Continuous biochemistry detection.
3rd, renal tissue frozen section kidney
The frozen section that thickness is 20 μm is carried out to renal tissue using LEICA freezing microtomes, the section for cutting is preserved
In -80 DEG C of refrigerators.
4th, the specific kidney injury Indexs measure in serum, urine.
5th, PAS dyeing.
6th, coloration result taken pictures, quantified.
Above two dyeing is taken pictures.And quantified for indexs such as Infarction volumes.
7th, statistical analysis
All data are given according to the mode of average value+standard deviation.Data are estimated using one-way analysis of variance, so
Student-Newman-Keuls post hoc test are used afterwards.P values are considered statistically significant less than 0.05.
2nd, experimental result and discussion
1st, the kidney infarct that NAD+ causes to ischemia surgery has protective effect, can substantially reduce serum urea nitrogen,
Creatinine level.
Control rats tail vein injection saline simultaneously carries out renal ischemic operation, and result of study finds, is urinated in serum
Plain nitrogen (BUN), creatinine (Scr) level are significantly raised, and experimental group rat tail vein injection NAD+ solution then can be reduced effectively
These parameters.Refer to Fig. 1.
2nd, NAD+ has protective effect to the renal damage that ischemia surgery causes.
Control rats tail vein injection saline simultaneously carries out renal ischemic operation, and result of study finds, renal tubule is damaged
Hinder index s NGAL (serum neutrophil gelatinase associated lipocalin), uKIM-1 (urine kidney injury molecule-1) significantly to rise
Height, PAS dyeing displays that renal damage increases, and experimental group rat tail vein injection NAD+ solution then can be reduced effectively
State damage.Refer to Fig. 2, Fig. 3.
Shown according to result above, NAD+ (NADH, Nicotinamide adenine
Dinucleotide, abbreviation NAD+) can effectively protect the kidney injury that renal ischemic causes, NAD+ lacks preparing preventing and treating kidney
There is significant application value in courageous and upright damage medicine.
Specific embodiment of the invention has been described in detail above, but it is intended only as example, and the present invention is not limited
It is formed on particular embodiments described above.To those skilled in the art, any equivalent modifications carried out to the present invention and
Replacement is also all among scope of the invention.Therefore, the impartial conversion made without departing from the spirit and scope of the invention and
Modification, all should be contained within the scope of the invention.
Claims (5)
1. application of the NADH in prevention or treatment renal ischemic injury medicine is prepared.
2. application according to claim 1, it is characterised in that the renal ischemic injury is serum urea nitrogen and creatinine
Rising, renal damage.
3. application according to claim 1, it is characterised in that the pharmaceutical dosage form is tablet, capsule, granule, drop
Pill, supensoid agent, syrup, enteric coated preparations or injection.
4. it is a kind of prevent or treatment renal ischemic injury medicine, it is characterised in that the medicine include nicotinamide adenine
Dinucleotides.
5. medicine according to claim 4, it is characterised in that NADH is the sole active of medicine
Composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710064412.5A CN106822170A (en) | 2017-02-04 | 2017-02-04 | Application of the NADH in prevention or treatment renal ischemic injury medicine is prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710064412.5A CN106822170A (en) | 2017-02-04 | 2017-02-04 | Application of the NADH in prevention or treatment renal ischemic injury medicine is prepared |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106822170A true CN106822170A (en) | 2017-06-13 |
Family
ID=59122806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710064412.5A Pending CN106822170A (en) | 2017-02-04 | 2017-02-04 | Application of the NADH in prevention or treatment renal ischemic injury medicine is prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106822170A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168236A (en) * | 2015-10-16 | 2015-12-23 | 上海市胸科医院 | Application of nicotinamide adenine dinucleotide in preparation of drug for preventing and treating heart ischemic injuries |
| CN105169367A (en) * | 2015-10-16 | 2015-12-23 | 中国人民解放军第三军医大学第一附属医院 | Application of TRPC6 in preparation of medicament for diagnosing and treating kidney ischemic reperfusion injury |
| CN106511366A (en) * | 2016-11-24 | 2017-03-22 | 重庆本贝得生物工程技术研究院有限公司 | Medicine for treating ischemic cerebral stroke as well as preparation method and application of medicine |
-
2017
- 2017-02-04 CN CN201710064412.5A patent/CN106822170A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168236A (en) * | 2015-10-16 | 2015-12-23 | 上海市胸科医院 | Application of nicotinamide adenine dinucleotide in preparation of drug for preventing and treating heart ischemic injuries |
| CN105169367A (en) * | 2015-10-16 | 2015-12-23 | 中国人民解放军第三军医大学第一附属医院 | Application of TRPC6 in preparation of medicament for diagnosing and treating kidney ischemic reperfusion injury |
| CN106511366A (en) * | 2016-11-24 | 2017-03-22 | 重庆本贝得生物工程技术研究院有限公司 | Medicine for treating ischemic cerebral stroke as well as preparation method and application of medicine |
Non-Patent Citations (2)
| Title |
|---|
| GI-SU OH 等: "Pharmacological activation of NQO1 increases NAD+ levels and attenuates cisplatin-mediated acute kidney injury in mice", 《KIDNEY INTERNATIONAL》 * |
| 刘学易 主编: "《儿科急症诊断治疗学》", 30 June 1999, 中国医药科技出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Song et al. | Antioxidant, anti-inflammatory and renoprotective effects of acidic-hydrolytic polysaccharides by spent mushroom compost (Lentinula edodes) on LPS-induced kidney injury | |
| Toor et al. | Structural insights into RNA splicing | |
| CN101222923A (en) | Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders | |
| CN110669149B (en) | Galacto-oligosaccharide and derivative and application thereof in medicines or health products for improving mitochondrial function and preventing and treating insulin resistance related diseases | |
| CN101361718A (en) | Stable preparation method of decitabine freeze-dry preparation | |
| CN103599071A (en) | Preparation method of polyinosinic-polycytidylic acid dry powder | |
| EP3468572B1 (en) | Compositions and methods for the treatment or prevention of oxalate-related disorders | |
| CN105395577A (en) | Composition capable of decreasing uric acid and preparation thereof | |
| CN112972488B (en) | Fucooligosaccharide with anti-hyperuricemia activity and preparation method and application thereof | |
| CN110812364A (en) | Application of galactooligosaccharide and derivatives thereof as SGLTs inhibitor | |
| JP2003511549A (en) | Compositions containing reduced maltooligosaccharide preservatives and methods of preserving substances | |
| CN111471078A (en) | Preparation method of uridine in tea with sparrow mouth and application of uridine in treatment of hyperuricemia | |
| CN105168236A (en) | Application of nicotinamide adenine dinucleotide in preparation of drug for preventing and treating heart ischemic injuries | |
| CN106822170A (en) | Application of the NADH in prevention or treatment renal ischemic injury medicine is prepared | |
| PT2289352T (en) | Agent for use in the case of fructose intolerance | |
| Surdyk et al. | Evaluation of the renal effects of ibuprofen and carprofen in euvolemic and volume-depleted dogs | |
| CN103641807B (en) | A kind of extracting method of apigenin, the pharmaceutical composition being used for the treatment of diabetes and application thereof | |
| CN103191145A (en) | Application of adenosine and derivatives thereof in prevention and treatment of medicament-induced liver injury | |
| CN104940181A (en) | Application of beta-hydroxybutyric acid or pharmaceutically acceptable salt thereof | |
| Zhang et al. | Combined QM (DFT)/MM molecular dynamics simulations of the deamination of cytosine by yeast cytosine deaminase (y CD) | |
| CN103054817B (en) | Vidarabine monophosphate pharmaceutical composition and preparation method thereof | |
| CN103040765B (en) | Pharmaceutical composition containing adenosine disodium triphosphate and preparation method of pharmaceutical composition | |
| Chang et al. | Effects of low molecular weight chitosans on aristolochic acid-induced renal lesions in mice | |
| CN115671118B (en) | Application of brown alginate oligosaccharides | |
| CN104884066A (en) | Amylase-activity-inhibiting composition containing chito-oligosaccharide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170613 |